Description
Vildagliptin SR 100mg + Dapagliflozin 10mg/5mg
Show additive HbA1c reduction (~1.5–2%) when DPP-4i and SGLT2i are combined.
Used in T2DM Patients uncontrolled on Metformin
Dosage:Available in oral tablet form. Once Daily
VYSOV D 100/10
Used in T2DM Patients uncontrolled on Metformin
Vildagliptin inhibits DPP-4, thereby prolonging incretin action (GLP-1 & GIP), enhancing glucose-dependent insulin release and suppressing glucagon, resulting in improved glycemic control. Dapagliflozin Selectively inhibits the Sodium–Glucose Co-Transporter 2 (SGLT2) in the proximal renal tubules.
